|
|
|
International Clinical Trials
|
Over 20 years after creating the Edmonton
Protocol, a process celebrated as a
possible ‘cure’ for diabetes, Dr James
Shapiro is at it again. This time, using
stem cells. The academic in Canada is
researching a new possibility of engineering
stem cells to become the insulin-producing
islet cells found in the pancreas.
Dr Shapiro explains: “The biggest
challenges with the Edmonton protocol
approach, where we use cells taken from
organ donors, are that we have to use
organ donors. When we think about the
enormous burden of diabetes worldwide,
463 million people with all forms of
diabetes, it’s been clear all along that there
would never be enough cells to go around
to treat that kind of patient base if the organ
donor approach became a therapy for all
diabetes. The second, perhaps bigger,
limitation is that those donor cells are
allogeneic. In other words, they’re foreign
to the body. Because of that, anti-rejection
drugs have to be given just like any other
organ transplant, like a heart, lung, or
liver, or those cells will be rejected by the
body. To overcome those two challenges, it
became clear to us that stem cells provided
a unique opportunity to fix both the supply
problem and the anti-rejection problem.”
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Born in Leeds, England, Professor James
Shapiro obtained his MD at the University
of Newcastle-upon-Tyne, UK, and trained
in Surgery at the University of Bristol, UK.
After joining the faculty at the University of
Alberta, Canada, in 1998, Professor Shapiro
led the clinical team with the ‘Edmonton
Protocol’ islet transplant success, and was
lead author on the 2000 NEJM study. He is
a Canada Research Chair in Transplantation
Surgery and Regenerative Medicine, and
has been the recipient of multiple awards,
including the Hunterian Medal from the
Royal College of Surgeons of England, the
Gold Medal in Surgery from the Governor
General of Canada, Physician of the Century,
and was recently named one of Nature
Biotechnology's most remarkable and
influential personalities.
|
|
|
|
|
|
 |
News and Press Releases |
 |
EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR KITE’S KTE-X19 FOR THE TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis --
-- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe --
More info >> |
|
 |
White Papers |
 |
|
Characterisation of Biopharmaceutical Proteins
Reading Scientific Services Ltd (RSSL)
Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >> |
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
|
_1.jpg)
